样式: 排序: IF: - GO 导出 标记为已读
-
Extraperitoneal robot assisted laparoscopic prostatectomy with Versius system: single centre experience Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-03-15 F. Dibitetto, C. Fede Spicchiale, R. Castellucci, S. Sansalone, A. Akhundov, L. Defidio, M. De Dominicis
-
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-03-13 Benedict Stanberry, Nikki Webber-Jones
-
MDT perspective: intraductal carcinoma of the prostate: implication for diagnosis and treatment Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-03-08 Hao Zeng, Sha Zhu, Jing Li, Ni Chen, Yao Zhu
Zhao et al. took the initiative of conducting the direct comparison of intraductal carcinoma of the prostate (IDC-P) and adenocarcinoma, by manually dissecting IDC-P from adenocarcinoma, followed by IHC validation, WES, RNA-seq and methylation sequencing [1]. It showed many interesting and new findings of IDC-P which are possibly underscored when previous researchers are using tumor mixtures as their
-
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-03-02 Neal Shore, Emmanuel Antonarakis, Ashley Ross, Catherine Marshall, Kelly Stratton, Adanma Ayanambakkam, Michael Cookson, Rana McKay, Alan Bryce, Marina Kaymakcalan
Background With the availability of second-generation androgen receptor inhibitors (SGARIs), the treatment landscape has changed dramatically for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). In clinical trials, the SGARIs (apalutamide, enzalutamide, darolutamide) increased metastasis-free survival (MFS), overall survival (OS), and patient quality of life compared to placebo
-
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-29 Primo N. Lara, Edward Mayerson, Erik Gertz, Catherine Tangen, Amir Goldkorn, Marta van Loan, Maha Hussain, Shilpa Gupta, Jingsong Zhang, Mamta Parikh, Przemyslaw Twardowski, David I. Quinn, Michael LeBlanc, Ian Thompson, Neeraj Agarwal
-
Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-28 Nicholas A. Zorko, Allison Makovec, Andrew Elliott, Samuel Kellen, John R. Lozada, Ali T. Arafa, Martin Felices, Madison Shackelford, Pedro Barata, Yousef Zakharia, Vivek Narayan, Mark N. Stein, Kevin K. Zarrabi, Akash Patniak, Mehmet A. Bilen, Milan Radovich, George Sledge, Wafik S. El-Deiry, Elisabeth I. Heath, Dave S. B. Hoon, Chadi Nabhan, Jeffrey S. Miller, Justin H. Hwang, Emmanuel S. Antonarakis
-
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-27 Surendra Dasari, Michael R. McCarthy, Antonina A. Wojcik, Beth A. Pitel, Arpan Samaddar, Burak Tekin, Rumeal D. Whaley, Aditya Raghunathan, Loren Herrera Hernandez, Rafael E. Jimenez, Brad J. Stish, R. Houston Thompson, Bradley C. Leibovich, Stephen A. Boorjian, R. Jeffrey Karnes, Daniel S. Childs, J. Fernando Quevedo, Eugene D. Kwon, Lance C. Pagliaro, Brian A. Costello, Kevin C. Halling, John C.
Primary prostatic adenocarcinoma (pPC) undergoes genomic evolution secondary to therapy-related selection pressures as it transitions to metastatic noncastrate (mNC-PC) and castrate resistant (mCR-PC) disease. Next generation sequencing results were evaluated for pPC (n = 97), locally advanced disease (involving urinary bladder/rectum, n = 12), mNC-PC (n = 21), and mCR-PC (n = 54). We identified enrichment
-
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-22 Ryan E. Fecteau, Bridget F. Koontz, Karen E. Hoffman, Susan Halabi, Lauren E. Howard, Monika Anand, Daniel J. George, Tian Zhang, William R. Berry, W. Robert Lee, Michael R. Harrison, Paul G. Corn, Andrew J. Armstrong
-
Hyperglycemia and microRNAs in prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-24 Valentina Russo, Lara Tamburrino, Simone Morselli, Cristina Sani, Elisabetta Baldi, Arcangelo Sebastianelli, Maria Rosaria Raspollini, Alessandra Mongia, Valentina Carradori, Eleonora Lallo, Armelle Munnia, Simonetta Bisanzi, Sara Marchiani, Carmen Visioli, Stefano Rapi, Sergio Serni, Marco Zappa, Francesca Carozzi, Marco Peluso
-
Variation in communication of side effects in prostate cancer treatment consultations Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-23 Timothy J. Daskivich, Aurash Naser-Tavakolian, Rebecca Gale, Michael Luu, Nadine Friedrich, Abhi Venkataramana, Dmitry Khodyakov, Edwin Posadas, Howard Sandler, Brennan Spiegel, Stephen J. Freedland
-
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-22 Zeynep B. Zengin, Nicholas C. Henderson, Joseph J. Park, Alicia Ali, Charles Nguyen, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Laura Graham, George Mo, Deepak Kilari, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Michael T. Schweizer, Andrew J. Armstrong, Rana R. McKay, Ajjai Alva, Tanya Dorff
-
High-intensity interval training versus moderate-intensity continuous training for localized prostate cancer under active surveillance: a systematic review and network meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-20 Qiyu Zhu, Xingyu Xiong, Qian Zheng, Qi Deng, Yun Hao, Dingbang Liu, Jiaming Zheng, Guangyue Zhang, Jiakun Li, Lu Yang
-
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-17 Masaki Shiota, Tokiyoshi Tanegashima, Shuichi Tatarano, Toshiyuki Kamoto, Hideyasu Matsuyama, Hideki Sakai, Tsukasa Igawa, Tomomi Kamba, Naohiro Fujimoto, Akira Yokomizo, Seiji Naito, Masatoshi Eto
-
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-14 Yu-Hsiang Lin, Horng-Heng Juang
I write in response to the intriguing article authored by Andrea-Grosso et al. [1], which explores the comparison between robot-assisted simple prostatectomy (RASP) and Holmium laser enucleation of the prostate (HoLEP). Several review articles have also delved into this topic, primarily focusing on parameters such as surgical time, hospital stay, and catheterization time. In these aspects, RASP often
-
Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-14 Luca Gemma, Alessio Pecoraro, Arcangelo Sebastianelli, Pietro Spatafora, Francesco Sessa, Rossella Nicoletti, Stavros Gravas, Riccardo Campi, Sergio Serni, Mauro Gacci
-
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-12 Andrew B. Nixon, Yingmiao Liu, Qian Yang, Bin Luo, Mark D. Starr, John C. Brady, Wm Kevin Kelly, Himisha Beltran, Michael J. Morris, Daniel J. George, Andrew J. Armstrong, Susan Halabi
-
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-12 Vincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese, Giuseppina Bruno, Cristian Lolli, Giuseppe Schepisi, Aldo Rosano, Guido Giordano, Marianna Garofoli, Vincenzo Emanuele Chiuri, Lucia Fratino, Elisa Zanardi, Luca Galli, Francesco Massari, Ugo Falagario, Pasquale Rescigno, Giuseppe Fornarini, Francesca Sanguedolce, Daniele Santini, Giuseppe Procopio, Orazio Caffo, Giuseppe Carrieri, Matteo
-
Does prostate cancer without cribriform pattern have metastatic potential? Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-10 Lisa J. Kroon, Sebastiaan Remmers, Eva Hollemans, Chris H. Bangma, Monique J. Roobol, Geert J. L. H. van Leenders
-
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-10 Osama Mosalem, Winston Tan, Alan H. Bryce, Roxana S. Dronca, Daniel S. Childs, Lance C. Pagliaro, Jacob J. Orme, Adam M. Kase
-
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC) Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-10 David R. Wise, Russell K. Pachynski, Samuel R. Denmeade, Rahul R. Aggarwal, Jiehui Deng, Victor Adorno Febles, Arjun V. Balar, Minas P. Economides, Cynthia Loomis, Shanmugapriya Selvaraj, Michael Haas, Michael H. Kagey, Walter Newman, Jason Baum, Andrea B. Troxel, Sarah Griglun, Dayna Leis, Nina Yang, Viktoriya Aranchiy, Sabrina Machado, Erika Waalkes, Gabrielle Gargano, Nadia Soamchand, Amrutesh Puranik
-
Incidence of prostate cancer in transgender women in the US: a large database analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-07 Matthew Loria, David Gilbert, Tomasz Tabernacki, Mart Andrew Maravillas, Megan McNamara, Shubham Gupta, Kirtishri Mishra
The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings
-
A non-invasive 25-Gene PLNM-Score urine test for detection of prostate cancer pelvic lymph node metastasis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-02-02 Jinan Guo, Liangyou Gu, Heather Johnson, Di Gu, Zhenquan Lu, Binfeng Luo, Qian Yuan, Xuhui Zhang, Taolin Xia, Qingsong Zeng, Alan H. B. Wu, Allan Johnson, Nishtman Dizeyi, Per-Anders Abrahamsson, Heqiu Zhang, Lingwu Chen, Kefeng Xiao, Chang Zou, Jenny L. Persson
-
Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-31 Eugenio Bologna, Leslie Claire Licari, Antonio Franco, Francesco Ditonno, Costantino Leonardo, Cosimo De Nunzio, Riccardo Autorino, Celeste Manfredi
-
The role of autophagy in prostate cancer and prostatic diseases: a new therapeutic strategy Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-31 Guilherme Lemos, Cícera Madri Alves de Souza Fernandes, Fábio Henrique Silva, Fabiano Beraldi Calmasini
-
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-24 Chloe Shu Hui Ong, Yu Xi Terence Law, Lin Kyaw, Qi Yang Lim, Tim Loke, Qing Hui Wu, Ho Yee Tiong, Edmund Chiong
-
Single port robot-assisted radical and simple prostatectomy: a systematic review and meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-23 Antonio Franco, Francesco Ditonno, Celeste Manfredi, Antony A. Pellegrino, Leslie Claire Licari, Eugenio Bologna, Carol Feng, Alessandro Antonelli, Marco De Sio, Cosimo De Nunzio, Francesco Porpiglia, Edward E. Cherullo, Jihad Kaouk, Simone Crivellaro, Riccardo Autorino
-
Does Retzius-Sparing robot-assisted radical prostatectomy guarantee optimal urinary continence recovery across all ages? Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-20 Paolo Dell’Oglio, Stefano Tappero, Ofir Maltzman, Alberto Olivero, Silvia Secco, Dario Di Trapani, Aldo Massimo Bocciardi, Antonio Galfano
-
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-17 Riccardo Lombardo, Giorgio Ivan Russo, Matteo Romagnoli, Giorgia Tema, Antonio Nacchia, Antonio Franco, Antonio Cicione, Giorgio Franco, Andrea Tubaro, Cosimo De Nunzio
-
Quality of information and appropriateness of Open AI outputs for prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-16 Riccardo Lombardo, Giacomo Gallo, Jordi Stira, Beatrice Turchi, Giuseppe Santoro, Sara Riolo, Matteo Romagnoli, Antonio Cicione, Giorgia Tema, Antonio Pastore, Yazan Al Salhi, Andrea Fuschi, Giorgio Franco, Antonio Nacchia, Andrea Tubaro, Cosimo De Nunzio
Chat-GPT, a natural language processing (NLP) tool created by Open-AI, can potentially be used as a quick source for obtaining information related to prostate cancer. This study aims to analyze the quality and appropriateness of Chat-GPT’s responses to inquiries related to prostate cancer compared to those of the European Urology Association’s (EAU) 2023 prostate cancer guidelines. Overall, 195 questions
-
A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-09 Kai Zhang, Phillip Stricker, Martin Löhr, Michael Stehling, Michel Suberville, Olivier Cussenot, Luca Lunelli, Chi-Fai Ng, Jeremy Teoh, Pilar Laguna, Jean de la Rosette
-
Genomic classifiers and prognosis of localized prostate cancer: a systematic review Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-10 Matthew J. Boyer, David J. Carpenter, Jeffrey R. Gingrich, Sudha R. Raman, Deepika Sirohi, Amir Alishahi Tabriz, Alexis Rompre-Broduer, Joseph Lunyera, Fahmin Basher, Rhonda L. Bitting, Andrzej Kosinski, Sarah Cantrell, Adelaide M. Gordon, Belinda Ear, Jennifer M. Gierisch, Morgan Jacobs, Karen M. Goldstein
-
An updated model for predicting side-specific extraprostatic extension in the era of MRI-targeted biopsy Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-05 Alberto Martini, Lieke Wever, Timo F. W. Soeterik, Arnas Rakauskas, Christian Daniel Fankhauser, Josias Bastian Grogg, Enrico Checcucci, Daniele Amparore, Luciano Haiquel, Lara Rodriguez-sanchez, Guillaume Ploussard, Peng Qiang, Andres Affentranger, Alessandro Marquis, Giancarlo Marra, Otto Ettala, Fabio Zattoni, Ugo Giovanni Falagario, Mario De Angelis, Claudia Kesch, Maria Apfelbeck, Tarek Al-Hammouri
-
Likelihood of sampling prostate cancer at systematic biopsy as a function of gland volume and number of cores Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-06 Michael E. Rezaee, Katarzyna J. Macura, Bruce J. Trock, Amin Herati, Christian P. Pavlovich, Misop Han, Dan Stoianovici
-
External validation of an algorithm to personalize nerve sparing approaches during robot-assisted radical prostatectomy in men with unilateral high-risk prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-04 Lara Rodriguez-Sanchez, Alberto Martini, Junlong Zhuang, Hongqiao Guo, Pawel Rajwa, Qusay Mandoorah, Luciano Haiquel, Shahrokh F. Shariat, Giorgio Gandaglia, Massimo Valerio, Giancarlo Marra
-
Addressing gaps in healthcare provider knowledge regarding germline testing for prostate cancer through development and testing of a virtual genetics board Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-03 Stacy Loeb, Heather H. Cheng, Channing J. Paller, Emily Weg, Jennifer Johnson, Laura Gross, Scott W. Keith, Jessica Russo, Feighanne Hathaway, Adrian Rivera, Veda N. Giri
Background Germline testing is important in prostate cancer and evaluation can be complex. Methods We instituted a monthly multi-disciplinary virtual genetics tumor board (7/2021-3/2022). Participants and panelists were surveyed on usefulness and acceptability. Results 101 participants attended a session, and 77 follow-up surveys were completed. Over 90% participants and 100% panelists endorsed usefulness
-
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2024-01-02 David E. Hinojosa-Gonzalez, Affan Zafar, Gal Saffati, Shane Kronstedt, Dimitar V. Zlatev, Mohit Khera
-
Prevalence of lower urinary tract symptoms in taxi drivers: a cross-sectional web-based survey Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-30 Vincenzo Li Marzi, Stefania Musco, Riccardo Lombardo, Antonio Cicione, Luca Gemma, Simone Morselli, Maria Lucia Gallo, Sergio Serni, Riccardo Campi, Cosimo De Nunzio
Purpose Aim of the study was to evaluate the prevalence of LUTS in taxi drivers. Methods Between February 24th 2021 and March 26th 2021 a web based survey was administered to Taxi drivers in the city of Florence. Taxi drivers were evaluated with baseline characteristics such as: age, BMI, smoking, career length, comorbidities, and treatment. LUTS were evaluated using the international prostate symptom
-
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-30 Shikuan Guo, Jingliang Zhang, Yingmei Wang, Jianhua Jiao, Zeyu Li, Chaochao Cui, Jian Chen, Wenhui Yang, Shuaijun Ma, Peng Wu, Yuming Jing, Weihong Wen, Fei Kang, Jing Wang, Weijun Qin
-
Concerns regarding prostate cancer screening guidelines in minority populations Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-19 Jamila Sweis, Bernice Ofori, Adam B. Murphy
Prostate-Specific Antigen (PSA) is a first-line recommended serum biomarker used for prostate cancer (PCa) screening. However, this test has critical limitations in specificity within the gray zone of PSA from 4–10 ng/ml. The low specificity for clinically significant Gleason grade group 2–5 (GG2-5) PCa leads to unnecessary negative biopsies, over-detection of indolent cancers, and over-treatment,
-
Which protocol for prostate biopsies in patients with a positive MRI? Interest of systematic biopsies by sectors Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-19 A. Zambon, T-A. Nguyen, A. Fourcade, T. Segalen, K. Saout, C. Deruelle, V. Joulin, V. Tissot, L. Doucet, G. Fournier, A. Valeri
-
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-14 Fabio Turco, Silke Gillessen, Giorgio Treglia, Karim Fizazi, Matthew R. Smith, Bertrand Tombal, Richard Cathomas, Consuelo Buttigliero, Massimo Di Maio, Marcello Tucci, Ursula M. Vogl
-
Molecular mechanisms underpinning favourable physiological adaptations to exercise prehabilitation for urological cancer surgery Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-18 James E. M. Blackwell, Nima Gharahdaghi, Colleen S. Deane, Matthew S. Brook, John P. Williams, Jonathan N. Lund, Philip J. Atherton, Ken Smith, Daniel J. Wilkinson, Bethan E. Phillips
-
Feasibility of a novel wearable thermal device for management of bothersome hot flashes in patients with prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-13 Pamela Peeke, Sonja K. Billes, Andrew Vetter, Nader Naghavi, Diana Le, Matthew Smith, Alicia K. Morgans
-
Association of prostate cancer with human papillomavirus infections: a case-control study Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-14 Shuo-Han Yin, Shiu-Dong Chung, Shih-Han Hung, Tsai-Ching Liu, Herng-Ching Lin
Background The highly oncogenic human papillomavirus (HPV) is associated with numerous cancer types. While the role of viruses in the development of certain cancers is well established, the association between HPV infections and prostate cancer remains a subject of ongoing debate. This study aimed to investigate a potential association of prostate cancer with HPV infections utilizing a case-control
-
The effects of glycemic index on prostate cancer progression in a xenograft mouse model Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-11 Gloria Cecilia Galván, Everardo Macias, Sergio Sanders, Adela Ramirez-Torres, Shannon Stock, Sungyong You, Celine E. Riera, Patrick Tamukong, Stephanie A. Smith-Warner, Jeanine M. Genkinger, Daniel J. Luthringer, Michael R. Freeman, Stephen J. Freedland
-
Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-06 Irene M. Shui, Mehmet Burcu, Changxia Shao, Cai Chen, Chi-Yin Liao, Shan Jiang, Razvan Cristescu, Ravi B. Parikh
-
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-06 Zhenchao Zhang, Rui Luo, William K. Kelly, Joshua Chen, Shane Donahue, Kevan Ip, Nathan R. Handley, William J. Tester, Miranda L. Tsang, Felix J. Kim, Ronald Myers, Grace Lu-Yao, Jian Gu, Jianqing Lin, Bingshan Li, Chun Wang, Hushan Yang
-
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-12-05 Yan Hiu Athena Lee, Jeremy Man Ho Hui, Chi Ho Leung, Christopher Tze Wei Tsang, Kyle Hui, Pias Tang, Jeffrey Shi Kai Chan, Edward Christopher Dee, Kenrick Ng, Sean McBride, Paul L. Nguyen, Gary Tse, Chi Fai Ng
-
Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET/CT imaging of prostate cancer—a systematic review and meta-analysis Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-28 Siyu Huang, Sean Ong, Dean McKenzie, Adam Mirabelli, David C. Chen, Thilakavathi Chengodu, Declan G. Murphy, Michael S. Hofman, Nathan Lawrentschuk, Marlon Perera
-
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-25 Sriram Deivasigamani, Eric S. Adams, Srinath Kotamarti, Mahdi Mottaghi, Terek Taha, Ali Aminsharifi, Zoe Michael, Denis Seguier, Thomas J. Polascik
-
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-25 Xingming Wang, Li Zhou, Lin Qi, Ye Zhang, Hongling Yin, Yu Gan, Xiaomei Gao, Yi Cai
-
Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-20 A. Saouli, A. Touzani, A. Martini, J. B. Beauval, H. Dergamoun, I. Ziouziou, N. Deffar, G. Ploussard, A. Ouzzane
-
Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-07 Mohamed E. Ahmed, Matthew S. Lee, Ahmed M. Mahmoud, Vidhu B. Joshi, Ajay Gopalakrishna, Raevti Bole, Rimki Haloi, A. Tuba Kendi, Michael S. Bold, Alan H. Bryce, Robert Jeffrey Karnes, Eugene D. Kwon, Daniel S. Childs, Jack R. Andrews
-
Editorial: new horizons in robotic platforms Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-06 Riccardo Lombardo, Matteo Romagnoli, Cosimo De Nunzio, Simone Albisinni
-
External validation of nomograms including MRI features for the prediction of side-specific extraprostatic extension Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-06 J. G. Heetman, E. J. R. J. van der Hoeven, P. Rajwa, F. Zattoni, C. Kesch, S. Shariat, F. Dal Moro, G. Novara, G. La Bombara, F. Sattin, N. von Ostau, N. Pötsch, P. A. T. Baltzer, L. Wever, J. P. A. Van Basten, H. H. E. Van Melick, R. C. N. Van den Bergh, G. Gandaglia, T. F. W. Soeterik
-
Digital informed consent for urological surgery - randomized controlled study comparing multimedia-supported vs. traditional paper-based informed consent concerning satisfaction, anxiety, information gain and time efficiency Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-11-04 Maximilian Haack, Nikita D. Fischer, Lisa Frey, Peter Sparwasser, Robert Dotzauer, Gregor Duwe, Axel Haferkamp, Hendrik Borgmann
-
Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-10-26 Steve Kaplan, Ronald P. Kaufman, Thomas Mueller, Dean Elterman, Bilal Chughtai, Daniel Rukstalis, Henry Woo, Claus Roehrborn
-
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-10-26 Robert Hugh Jones, Karim Fizazi, Nicholas D. James, Teuvo L. Tammela, Nobuaki Matsubara, Frank Priou, Philippe Beuzeboc, Thierry Lesimple, Petri Bono, Vesa Kataja, Jorge A. Garcia, Andrew Protheroe, Neal Shore, John Aspegren, Heikki Joensuu, Iris Kuss, Sabine Fiala-Buskies, Egils Vjaters
Background In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. Methods Treatment-emergent adverse events (TEAEs) for patients receiving darolutamide for a median of 38 months (n = 13) are described in this pooled analysis of individual patient data from phase 1/2 studies. Results All patients
-
Impact of peritoneal reconfiguration on lymphocele formation after robot-assisted radical prostatectomy with pelvic lymph node dissection: a systematic review and meta-analysis of randomized controlled trials Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-10-24 Francesco Ditonno, Celeste Manfredi, Antonio Franco, Alessandro Veccia, Fabrizio Dal Moro, Cosimo De Nunzio, Marco De Sio, Alessandro Antonelli, Riccardo Autorino
-
Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120 Prostate Cancer Prostatic. Dis. (IF 4.8) Pub Date : 2023-10-23 Pei Liang, Susanne M. Henning, Tristan Grogan, David Elashoff, Jonathan Said, Pinchas Cohen, William J. Aronson